Recent Updates
Recently added Catalysts

Thyroid Eye Disease: two biotech companies racing to a treatment

Immunology & InflammationConcentrated betData as of 2026-09-04

Competitors2in the clinic
Median market cap$2.8Buniverse median $1.20B
Allocated capital$3.6B$5.7B competing
Phase 3 or filed20 mid, 0 early
Pure plays1this indication only
Capital rank51/299crowding rank 73

Thyroid Eye Disease is a two-horse race: Zai Lab (ZLAB, $3.1B) against Viridian Therapeutics (VRDN, $2.6B).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $3.6B of allocated capital sits on the pair.

ZLAB carries 54% of the $5.7B competing here, so the pair is far from evenly matched.

$3.6B of allocated capital sits in Thyroid Eye Disease, 51st of 299 indications, and 1 of the 2 companies are pure plays that trade on this indication alone.

Companies developing drugs for Thyroid Eye Disease 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
ZLABZai LabZL-1109Phase 31$3.1BNo3 31 Dec 2026
VRDNViridian TherapeuticsVRDN-003Phase 33$2.6BYes1 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. ZLAB holds 54% of the $5.7B competing in this indication.

Why Thyroid Eye Disease is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Thyroid Eye Disease has 2 competitors and a median of $2.8B.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

IgA Nephropathy4 companies · $3.6B · median $1.8BConcentrated betSjögren's Disease4 companies · $4.4B · median $1.7BConcentrated betWarm Autoimmune Hemolytic Anemia2 companies · $2.4B · median $3.8BConcentrated betAlopecia Areata3 companies · $2.2B · median $1.6BConcentrated betWrinkles1 company · $2.2B · median $11.0BUncontestedPrimary Biliary Cholangitis1 company · $2.2B · median $6.5BUncontestedPrimary Sclerosing Cholangitis1 company · $2.2B · median $6.5BUncontestedCrohn's Disease4 companies · $5.1B · median $714MOrphan corner

Thyroid Eye Disease pipeline questions

Which biotech companies are developing drugs for Thyroid Eye Disease?

Zai Lab (ZLAB, ZL-1109, Phase 3); Viridian Therapeutics (VRDN, VRDN-003, Phase 3). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Thyroid Eye Disease.

How advanced is the Thyroid Eye Disease pipeline?

Of the 2 clinical-stage programmes in Thyroid Eye Disease, 2 are in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Which company leads the Thyroid Eye Disease field?

ZLAB is the largest developer in Thyroid Eye Disease, holding 54% of the $5.7B of market capitalisation competing in the indication. The median competitor is worth $2.8B.

When is the next Thyroid Eye Disease catalyst?

The next dated catalyst in Thyroid Eye Disease is ZLAB on 31 Dec 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map